Article and Video CATEGORIES

Cancer Journey

Search By

Karen Reckamp, MD, MS, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.

Lung Cancer Video Library - The Role of Angiogenesis in Previously Treated NSCLC
Wed, 03/07/2018 - 13:46
Karen Reckamp, MD, MS, GRACE Faculty



The Role of Angiogenesis in Previously Treated Non-Small Cell Lung Cancer (NSCLC) Presented by Karen Reckamp, MD, MS Co-Director, Lung Cancer and Thoracic Oncology Program Medical Director, Clinical Research Operations City of Hope Comprehensive Cancer Center Duarte, California


I’m Karen Reckamp, I’m the medical director of the Thoracic Oncology Program and the medical director of Clinical Research at City of Hope Comprehensive Cancer Center in Duarte, California. The role of angiogenesis in lung cancer is really blood vessels feed the tumor and provide the nutrients that the tumor needs to grow and spread and cause metastases. Anti-angiogenic therapy generally in the form of antibody for non-small cell lung cancer can block that and inhibit blood vessel growth thus stunting tumor growth and the ability to develop metastases. The drug that is approved for second-line therapy with chemotherapy Docetaxel is Ramucirumab. This is an anti-VEGF receptor antibody and it binds to the receptor to block the blood vessel growth and inhibit tumor growth. It does this well in conjunction with chemotherapy. There was a clinical trial evaluating Ramucirumab and Docetaxel versus Docetaxel alone as second-line therapy following progression on initial chemotherapy for metastatic non-small cell lung cancer. This included both patients with non-squamous histology and with squamous histology so all non-small cell lung cancers. Patients had an improvement in time to the tumor growth, in overall survival time, and in the amount of the tumor shrinkage for the combination of Ramucirumab and Docetaxel over Docetaxel alone. There are more side effects with the combination and so more people had fevers and low blood counts, but overall the patients did well with both and had limited number of reasons to discontinue. There were similar numbers of patients who died from the treatment in both arms.

 We would like to thank the following companies for their support of this program











Next Previous link

Previous PostNext Post

Related Content

Community Forum

Hi CDaniele,
Welcome to Grace. If the TKI is working except for one or 2 places local treatment such as radiation can be used to get rid of the resistant cells...

I forgot to tell you that Grace is having its annual OncTalk live forum online Saturday, Dec. 11 at 8 am Pacific and 11 am Eastern
It will be invaluable to...

This is indeed a happy Thanksgiving in our house. I'll post about it at soon but we've just come out of a dark place and are feeling so hopeful today.

Hi and welcome to Grace.  I'm sorry your sister-in-law is going through this it's so unsettling, to say the least.  Cancer travels through the lymph system but also through blood vessels. ...

Hi Tronique,  I can't say if you do or don't have a pancoast tumor but it sounds like there are a dozen other reasons you're having your symptoms and several reasons...

Recent Comments

2021 OncTalk Dec. 11 Free Online with Expert Faculty
By JanineT Forum … on Sat, 11/27/2021 - 13:49
By JanineT Forum … on Fri, 11/26/2021 - 12:28
Happy Thanksgiving
By JanineT Forum … on Wed, 11/24/2021 - 12:38
Hi and welcome to Grace.  I'm
By JanineT Forum … on Mon, 11/22/2021 - 10:04